Overview

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multicenter, dose escalation study evaluating the tolerability, safety, pharmacokinetics and preliminary efficacy of veliparib in combination with carboplatin and weekly paclitaxel in Japanese subjects with ovarian cancer.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Veliparib